Abstract Mycosis fungoides (MF) and Sézary syndrome (SS) comprise the majority of cutaneous T-cell lymphomas (CTCLs). Despite the rarity of these diseases, new insights into the epidemiology and pathophysiology of MF/SS are rapidly emerging that should lead to improved diagnosis and treatment. Here we discuss updates on MF/SS incidence, prognosis and survival, clinical variants, disease biomarkers, pathophysiology, genetics, and disease progression.
Introduction
Cutaneous T-cell lymphomas (CTCL) are a group of lymphoproliferative disorders comprised of clonally derived, primarily CD4+, skin-homing malignant T-cells. Of all the cutaneous lymphomas evaluated from 2001-2005, CTCLs accounted for 71 %, with Mycosis fungoides (MF) and Sézary syndrome (SS) representing the most common subtypes (54 % of all CTCLs) [1] . MF is characterized by the proliferation of neoplastic, epidermotropic, small to medium-sized T-lymphocytes with distinctive cerebriform nuclei. Its classic clinical manifestations vary from the presence of patches, plaques, tumors or erythroderma, but can often mimic other inflammatory dermatoses. SS, a leukemic variant of CTCL, is defined by the triad of erythroderma, generalized lymphadenopathy, and the presence of neoplastic T-cells in the skin, lymph node and peripheral blood [2] . In both subtypes, the neoplastic cell is most often characterized by a CD4+CD7-and/or CD4+CD26-phenotype [3] .
MF, in its early stages, typically exhibits an indolent clinical course with occasional progression of disease while SS tends to exhibit a more aggressive course. Ultimately, prognosis is determined by initial clinical presentation and disease stage. To date, due to small numbers of patients, a lack of consistent staging and outcome measures in some older studies, and few prospective randomized controlled clinical trials, it is difficult to definitively ascertain if our treatment modalities have improved overall survival in this orphan disease, making further insight into the potential etiologies/pathophysiology of CTCL crucial to developing novel targeted therapies for this disease. This review will highlight contributions to the understanding of CTCLs, namely MF and SS, published in the literature recently, with particular focus on reports from this last year (since July 2011) through October 2012.
(0.01/100,000) during this reporting period was slightly increased vs. that previously published by Bradford et al. for 2001 Bradford et al. for -2005 (MF incidence 0.41/100,000 person-years). Similar to the previously reported data, increased incidence was observed in males (incidence rate ratio of 1.57 vs. females) and blacks (IRR 1.55 vs. males). In addition, blacks at diagnosis had a lower median age (53 y.o. vs. 63 y.o. for whites) and presented on average at higher stages than white patients. Also similar to prior studies, multivariate analysis demonstrated that age >60, black race, and advanced stage were associated with worse overall survival.
Saundes et al. reported on MF/SS and overall CTCL incidence in Norway from 1980-2003 [5] . Overall incidence of MF increased 9 % per 5-year period (from 0.15/100,000 person years during1980-84 to 0.18/100,000 during [2000] [2001] [2002] [2003] . Their incidence rates were comparable to those published for Germany, but less than that observed in the USA, Finland, and Israel.
Prognosis and Survival of MF and SS
Over the past 3 years, survival data from two of the largest single-center series of MF/SS patients have been published using updated 2007 International Society for Cutaneous Lymphoma-European Organization for Research and Treatment of Cancer (ISCL/EORTC) staging criteria. Agar et al. from the UK analyzed their cohort of 1,502 MF/ SS followed from 1980-2009 for overall survival (OS), disease specific survival (DSS) and risk of disease progression (RDP) [6••] . Seventy-one percent of these patients presented with early stage (Stage IA, IB, IIA) disease. Disease progression to a higher stage occurred in 34 % of patients; 25 % patients ultimately died of their disease. Patch/plaque skin disease patients had worse overall survival than those with only patch disease (the previous earlier staging system T1 or T2 categories did not distinguish between patch vs. patch/plaque). In multivariate analysis, advanced skin (T) stage, increased lactate dehydrogenase (LDH), folliculotropic variant, and B0b status (presence of a relevant T-cell receptor clonal population in peripheral blood in the absence of overt Sézary cells) were factors associated with worse OS and increased RDP.
During [10] . The mean age of diagnosis in their patient population was 43 years old, which is younger than comparable patients with early stage MF. Half of the patients were younger than 35 years old. All patients, except for one, had Fitzpatrick type IV skin. In the majority (5/ 8 patients), hyperpigmented lesions were the sole manifestation of their disease. In all eight patients, biopsies showed classic findings for CTCL with a prevalence of CD8+ Tcells in the majority and a variable number of melanophages in the dermis. Patients exhibited an indolent disease course after 3.8 years of follow-up on skin directed therapies alone.
Intertriginous Mycosis Fungoides
Gammon and Guitart describe three patients (two men and one woman with a mean age of 43 years) who present with intertriginous tumors without antecedent patch or plaque stage disease, and with a prominent B-cell component on histopathology [11] . Clinically, these patients had tumors and thick plaques primarily on intertriginous skin, most commonly on the axillary and inguinal folds. Biopsies of the lesions revealed a nodular and diffuse infiltrate of polymorphous mediumsized atypical lymphocytes. Molecular T-cell receptor (TCR) gene rearrangement showed a positive clonal population in all three patients. Two out of three patients had evidence of peripheral blood involvement. Immunohistochemistry (IHC) revealed a prominent follicular T-cell population. These patients demonstrated progression of their disease despite aggressive therapeutic interventions.
Dyshidrotic Mycosis Fungoides
Diehl et al. report a case of a 73-year-old female with an 8-year history of vesicles and fissures accentuated on the plantar area of her feet [12] . Clinically, she was thought to have an overlap of dyshidrotic eczema and tinea pedis. However, her findings did not improve with application of topical antifungals or corticosteroids. Her refractory nature prompted her physicians to perform a punch biopsy. Histopathology revealed epidermotropism and syringotropism of atypical lymphocytes, intraepidermal vesicle formation and Pautrier's microabscesses. IHC demonstrated a skewed CD4:CD8 ratio. Her eruption eventually cleared with ultraviolet B (UVB) phototherapy.
Trauma Induced Mycosis Fungoides
No clear trigger has been identified in either causing or driving the majority of MF cases. Paul and Duvic describe four male patients, ages 33-46, who presented with localized biopsy proven MF in an area of trauma [13] . They exhibited a median time of 10 years between exposure and diagnosis. While the reports are anecdotal and recall bias cannot be avoided, it is interesting to hypothesize that chronic antigenic stimulation leading to chronic inflammation with a clonal T-cell population could be induced by trauma.
Medication Induced or Exacerbated Mycosis Fungoides
In a subset of MF/SS patients, chronic antigenic stimulation may play a role in disease development and a wide variety of medications can rarely idiosyncratically cause skin reactions that mimic or even trigger MF/SS. Jahan-Tigh et al. prospectively assessed use of the antihypertensive medication hydrochlorothiazide (HCTZ) in 1,443 MF/SS patients at MD Anderson [14] . Of the total group, 56.5 % of patients had hypertension and 25.2 % of this hypertensive group (205 pts) were taking HCTZ at initial staging, with 28 % of them starting within 1 year of development of skin rash. Additionally, 125 patients underwent trials off medication and 36 of them (28.8 %) experienced complete or partial remission of MF/SS after discontinuing HCTZ. Three patients underwent HCTZ rechallenge and developed MF lesions that resolved or improved with discontinuation.
Granuloma Annulare-Like Granulomatous Mycosis Fungoides
Mizuno et al. report a case of a 62-year-old woman with pink-brown annular lesions on her waist [15] . She was given the diagnosis of granuloma annulare and was treated with topical steroids for 10 years prior to a definitive biopsy. A computed tomography (CT) scan revealed prominent lymphadenopathy. Subsequent axillary lymph node biopsy revealed granulomas composed of epithelioid cells and multinucleated giant cells without necrosis. Histopathology revealed CD8+ dermal lymphocytes, epithelioid cells, and foreign body-type multinucleated giant cells. Her cutaneous eruption improved with PUVA therapy (photochemotherapy) while her lymphadenopathy persisted.
Cutis Laxa-Like Mycosis Fungoides
Lopez Aventin et al. describe the case of a 75-year-old woman who presented with loosening of her skin on her trunk and extremities, sparing her flexural skin [16] . These lesions were on sun-protected areas without a history of preceding inflammatory lesions. A biopsy revealed atrophy of the epidermis, focal epidermotropism of atypical lymphocytes, full thickness dermal and interstitial infiltrate of small lymphocytes (some with atypia). Elastic tissue stain showed focal reduction and fragmentation of the elastic fibers without phagocytosis. The patient did not have any evidence of systemic disease. Her eruption remained stable for 32 months of follow-up. While patients with the granulomatous slack skin variant of MF may have similar lesions clinically, they tend to have accentuation along flexural surfaces, and a granulomatous infiltrate with prominent elastophagocytosis on biopsy. Lacking these findings, cutis laxa-like MF may be a novel variant.
Large Cell Transformation
In MF/SS, the development of large cell transformation (LCT) may portend a worse prognosis with patients, often exhibiting an aggressive clinical course. LCT is defined histologically as the presence of tumor cells with enlarged nuclei (4x the size of normal lymphocytes) in at least 25 % of total infiltrate and can occur in skin, nodal, or blood compartments. Typically LCT is observed in the setting of clinical worsening of disease [17] : i.e., a new nodularity within a preexisting patch/plaque, an abrupt onset of new nodules/plaques, rapid growth of plaques/tumors, or increasing or bulky lymphadenopathy.
In large outcome studies, LCT is associated with poor survival and is an independent predictor of risk of disease progression [6••] . Previously it was not clear which LCT patients would exhibit a more rapid course requiring more aggressive therapy. Benner et al. identified 100 patients with evidence of LCT to further subclassify that patient population and identify those as risk for more aggressive disease [18••] . Of those 100 patients, 75 patients had evidence of skin disease only, 19 had evidence of skin and lymph node involvement, and six had evidence of nodal disease only.
The male to female ratio was 1.8:1 and the median age at diagnosis was 68. The median time from diagnosis of MF on biopsy to LCT was 10 months. No patients had evidence of stage IA disease at diagnosis of LCT, reaffirming its relatively indolent clinical course. Only 18 patients achieved short-lived remission with a median survival of 24 months after LCT. Reduced DSS was associated with CD30 negativity of transformed large cells, folliculotropic lesions, greater extent of skin lesions, and extracutaneous transformation.
Biomarkers of Disease
Early diagnosis of MF/SS has an impact on stage at presentation, prognosis and timely initiation of necessary therapeutic agents. However, as demonstrated by its myriad of clinical variants, MF/SS in their early forms may be difficult to distinguish from other benign dermatoses and it may take several years and multiple biopsies before a definitive diagnosis is made. As a result, we continue to search for distinctive biomarkers to aid in early identification of the malignant T-cell population and to alleviate the recurrent diagnostic dilemma when patients present with subtle early MF and few circulating malignant T-cells. [19•] . They were able to identify 19 genes with a greater than 2-fold increase in expression as compared to CD and NS. The genes identified play a role in early T-cell development, immune regulation, signal transduction, cell adhesion and proapoptosis regulation. Two genes in particular demonstrated marked upregulation, TOX (regulator of early T-cell development) and PDCD1 (pro-apoptosis regulator). Of the two, TOX was found to specifically label CD4+ T-cells in early MF as compared to patients with CD or NS.
Zhang et al. evaluated 21 patients with early MF in comparison to chronic dermatitis (CD) and normal skin (NS)
T-Plastin (PLS3) is an actin-bundling protein that is not typically expressed on cells of hematopoetic origin. However, Jones et al. reaffirm previous reports of increased TPlastin expression in patients with SS [20•] . Of patients with SS, 60 % had T-Plastin expression on CD3+CD4+CD26-cells as compared to 38 % of patients with MF. Sequencing of the gene did not reveal any mutations, but methylation analyses revealed site-specific hypomethylation that may contribute to its aberrant expression.
MicroRNA (miRNA) profiling is another diagnostic tool to further distinguish patients. Ralfkiaer et al. evaluated expression levels of miRNAs from 198 patients with CTCL, peripheral T-cell lymphoma (PTL) and benign skin diseases including psoriasis and other dermatoses [21•] . With greater than 90 % accuracy, they identified induction of miR-326, miR-663 and miR-711 and suppression of miR-203 and miR-205 in patients with CTCL. This distinction was not skewed when psoriatic lesions were treated with topical steroids.
Finally, the cell surface marker programmed death-1 (PD-1) has also been identified as a potential marker for patients with SS as compared to normal controls with increased expression identified on both CD4+CD26-and CD4+CD26+ cells [22•] . Blockade of PD-1 or its ligand PD-L1 may be a potential target for progression of disease and restoration of immunologic function. Recent evidence suggests that patients with small-medium pleomorphic Tcell lymphoma also have increased expression of PD-1 on their atypical cells as compared to patients with MF or CD30+ lymphoproliferative disorders [23•] .
Pathophysiology
Patients with CTCL, especially SS, demonstrate profound immunologic abnormalities. They commonly display a dominant Th2 cytokine profile characterized by increased levels of IL-4 and IL-5 [24] with decreased levels of Th1 cytokines such as IL-2 and IFN-γ [25] , resulting in reduced cell-mediated immunity [26] Low herpesvirus entry mediator (HVEM) expression may play a role in this skewed profile. The interaction of HVEM on dermal fibroblasts with its ligand LIGHT on T-cells is important for an adequate Th1 response. Miyagaki et al. demonstrate a correlating decrease in expression of HVEM with advanced disease [27] . This low level expression, most notable in patients with SS, may further contribute to the skewed Th2 cytokine profile observed in these patients.
Dysregulation of the immune response is further heightened by an increase in IL22 production by Th22 cells and a decrease in IL17 production by Th17 cells with enhanced expression of IL22 correlating with advanced disease [28] . Increased Th2 cytokine production may also result in suppression of IL17 production resulting in a relative lack of neutrophils in lesional skin. In addition, neutrophils in patients with SS demonstrate decreased phagocytosis and intracellular killing towards klebsiella pneumoniae [29] . This finding is even more pronounced in patients who have evidence of recurrent infections. As a result, endogenous immunosuppression mediated by a lack of effective cell-mediated immunity leads to a substantially increased risk for opportunistic infections [30] .
A skewed cytokine production is only one piece of the puzzle. B-cell activating factor (BAFF), a member of the tumor necrosis factor family, may also play a role in the development of CTCL as well as other T-cell-mediated diseases. Ohmatsu et al. demonstrate higher levels of BAFF in the skin and sera of patients with CTCL that correlates with disease severity and change in disease stage [31] . However, patients with psoriasis demonstrated a similar increase in BAFF as compared to normal controls. BAFF may play a role in maintaining B-cells and subsequently activating T-cells, exacerbating T-cell-mediated diseases. [32] . Mast cells in patients with cutaneous lymphoma were extensively degranulated as compared to normal patients. In addition, CTCL cells that were incubated with mast cell supernatant demonstrated enhanced proliferation and production of proinflammatory cytokines. Mast cell deficient mice exhibit decreased growth of EL4 tumors (mouse T-cell lymphoma line) providing an elegant in vivo model for these in vitro discoveries. Future studies targeting mast cells or their mediators may be a promising therapeutic approach.
Finally, tumor growth and progression is reliant on angiogenesis, with angiogenin playing a pivotal role in that process. In patients with CTCL, those who are erythrodermic, indicating a higher T stage, have increased serum levels of angiogenin [33] . This implies a role in the progression of cutaneous disease and prognosis. However, Miyagaki et al. do not follow patients longitudinally to analyze serum angiogenin levels over time and correlate its levels with a change in disease stage. If identified as playing a role, it too may be a desirable future target.
Disease Progression
The increase in the number of malignant T-cells in advanced CTCL is likely partially due to resistance to apoptosis resulting in increased T-cell proliferation. Stutz Tumor suppressor genes similarly play an important role in cell cycle regulation and tumor progression. A majority of SS cell lines and patients with SS exhibit TP53 mutations and impaired p53 signaling with resistance to treatment with nutlin-3 (a common activator of the p53 pathway) [35•] . Some cell lines show a homozygous nonsense or missense mutation. While SS cells are relatively resistant to activation of p53 by nutlin-3a, combination treatment of cell lines with both nutlin-3a and chemotherapies (including doxorubicin and bortezomib) results in increased cytotoxicity and efficacy of those agents [36] .
Dysregulated proliferation of neoplastic T-cells may be further driven by expression of certain cell signaling proteins. Nuclear expression of pro-IL-16 plays a role in maintaining a cellular resting state. However, circulating T-cells in patients with CTCL express decreased levels of pro-IL-16, leading to downstream overexpression of Skp2 and further disrupting T-cell quiescence [37] . In addition, patients with Sézary syndrome demonstrate constitutive STAT3 expression in vivo. Van der Fits et al. demonstrate increased circulating IL-21 as compared to healthy donors and those with benign erythroderma, and a corresponding increase in IL-21R expression on CD4+ T-cells, resulting in activation of STAT3 [38] . Not only is IL-21 a potent activator of STAT3, its expression is also regulated by STAT3, resulting in a positive feedback loop.
Genetics
Genome-wide analyses are valuable research tools to better understand the pathogenesis of MF/SS and to identify novel targeted therapies. Lin et al. identified significant DNA copy number alterations in patients with SS, including gains on 8q and 17q and deletions on 17p and chromosome 10 [39] . Van Kester et al., through a meta-analysis of publicly available gene expression data sets, identified 989 aberrantly expressed genes in patients with tumor stage MF, 718 of which are statistically significant [40] . They were able offer further insight into the immunophenotype of tumor stage MF revealing overexpression of IFN responsive genes, interleukin/chemokine genes and receptors, and downregulation of IL11RA. In addition, multiple genes were identified that are involved in mitosis, cell division, cell cycle and DNA replication including genes not previously reported in the literature (IDO2, RRM2, CD74, TOP2A, GTSF1, TRIP13, and NFKBIZ). Further investigation is necessary to determine the importance of these gene expression abnormalities and their potential role as diagnostic markers or therapeutic targets. They reported that SS patients were particularly responsive to low dose alemtuzumab treatment (monoclonal antibody directed against cell surface CD52 expressed on T-and B-cells, natural killer cells, dendritic cells), which is mediated by neutrophildependent, antibody-dependent cell-mediated cytotoxicity (ADCC) which is present in the blood but not in the epidermis. They also demonstrate that skin immune surveillance is not compromised by alemtuzumab since skin-resident effector memory T-cells are not affected by alemtuzumab, and despite marked depletion of peripheral blood central memory T-cells, these patients do not experience opportunistic infections after alemtuzumab treatment.
Mycosis Fungoides vs. Sézary Syndrome

Conclusions
MF and SS appears to be slightly increasing in incidence over the past 10 years and while the precise triggers remain unclear, improved inmmunohistochemistry, immunologic and molecular biological techniques and updated clinical staging recommendations have enabled us to better characterize different subsets of patients in terms of accurate staging, genetic expression, clinical presentation and behavior, and overall prognosis.
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